Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2025-03-26 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
关于审计机构变更项目合伙人及项目质量控制复核人的公告
Audit Report / Information Classification · 95% confidence The document is an announcement from a company about the change of audit engagement partners and quality control reviewers for the audit firm appointed for the company's 2024 financial report and internal control audit. It references the audit firm, the partners involved, their qualifications, and confirms no impact on the audit work. The document does not contain actual audit reports or financial statements but is an announcement about personnel changes related to the audit engagement. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and related information such as changes in audit personnel, but excludes full annual reports. The document is not a full annual report (10-K), nor a regulatory filing or report publication announcement. Therefore, the best classification is AR with high confidence. FY 2024
2025-03-26 Chinese
第九届监事会第二十六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolution passed at the 26th meeting of the 9th Supervisory Board of Northeast Pharmaceutical Group Co., Ltd. It includes details about the meeting date, attendance, voting results, and references another announcement for detailed content. The document is short (619 characters) and serves as a meeting resolution announcement rather than a full report or financial statement. It does not contain financial data, audit information, or management discussion. It is not a regulatory certification or officer attestation. The content fits best under a regulatory announcement category related to board or supervisory meetings but does not specifically announce changes in board or management personnel. Given the options, the closest fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-03-26 Chinese
第九届董事会独立董事2025年第一次专门会议审议意见
Board/Management Information Classification · 95% confidence The document is a formal opinion statement from independent directors regarding a specific agenda item about related party transactions for the year 2025. It references compliance with stock exchange listing rules and company bylaws. The content is focused on board-level review and approval of corporate governance matters, specifically related to independent directors' opinions on related party transactions. It does not contain financial statements, earnings data, or detailed financial analysis. It is not a full annual or interim report, nor an earnings release or audit report. It is a board/management information type document concerning governance and board decisions. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and focused on board opinions, consistent with MANG filings.
2025-03-26 Chinese
关于2022年限制性股票激励计划预留授予部分第二个解除限售期解除限售股份上市流通的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from a company about the lifting of restrictions on a portion of restricted stock awards under a 2022 restricted stock incentive plan. It includes information about board and supervisory meetings, legal opinions, approval processes, performance conditions, and the number of shares becoming unrestricted and available for trading. The document is not a financial report, earnings release, or management discussion, but rather a formal announcement related to stock incentive plan implementation and share unlocking. It does not fit categories like Annual Report, Earnings Release, or Management Reports. It is also not a proxy solicitation or voting results announcement. The document is a regulatory announcement about the unlocking of restricted shares and related corporate actions, which fits best under Regulatory Filings (RNS). The document length is about 9,396 characters, which is substantial but it is not a report itself, rather an announcement of corporate actions and approvals related to stock incentives.
2025-03-11 Chinese
关于控股股东一致行动人增持公司股份计划时间过半的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a share increase plan by a controlling shareholder and its concerted parties. It details the status of the shareholding increase plan, the amount intended to be increased, the timeline, and compliance with regulatory requirements. There are no financial statements or detailed financial data presented, nor is this a report or presentation. The document is a regulatory announcement about shareholding changes and plans, specifically an update on a capital increase plan by a major shareholder. This fits best under Capital/Financing Update (CAP) as it relates to financing activities and capital structure changes.
2025-03-11 Chinese
监事会关于第九届监事会第二十五次会议相关事项的核查意见
Transaction in Own Shares Classification · 95% confidence The document is a supervisory board opinion on matters related to the company's 2022 restricted stock incentive plan, including approval of lifting restrictions on certain shares and a proposal to repurchase and cancel some restricted shares. It discusses compliance with stock incentive management rules and does not contain financial statements or detailed financial data. The document is a formal opinion or announcement related to share repurchase and stock incentive plans, not a full financial report or earnings release. Given the focus on repurchase and cancellation of shares, the most appropriate classification is Transaction in Own Shares (POS). The document length is short and contains substantive content, so it is not a mere announcement or certification.
2025-03-05 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.